6 hours Ago By ABMN Staff
Assetmark Inc. raised its stake in shares of Fortrea Holdings Inc. ( NASDAQ:FTRE – Free Report ) by 154.
9% during the fourth quarter, Holdings Channel reports. The firm owned 41,395 shares of the company’s stock after buying an additional 25,157 shares during the quarter. Assetmark Inc.
’s holdings in Fortrea were worth $772,000 at the end of the most recent quarter. Several other institutional investors have also added to or reduced their stakes in FTRE. Covestor Ltd increased its position in shares of Fortrea by 102.
4% during the third quarter. Covestor Ltd now owns 2,763 shares of the company’s stock valued at $55,000 after buying an additional 1,398 shares during the period. Whalen Wealth Management Inc.
bought a new stake in Fortrea during the 4th quarter valued at approximately $204,000. Allspring Global Investments Holdings LLC boosted its position in Fortrea by 21.9% during the 4th quarter.
Allspring Global Investments Holdings LLC now owns 11,073 shares of the company’s stock valued at $207,000 after acquiring an additional 1,986 shares in the last quarter. Centiva Capital LP purchased a new position in shares of Fortrea during the 3rd quarter worth approximately $220,000. Finally, Verition Fund Management LLC bought a new position in shares of Fortrea in the 3rd quarter worth approximately $220,000.
Fortrea Price Performance Shares of NASDAQ FTRE opened at $10.05 on Wednesday. The firm has a market cap of $906.
51 million, a P/E ratio of -2.94, a PEG ratio of 1.78 and a beta of 1.
34. Fortrea Holdings Inc. has a twelve month low of $9.
55 and a twelve month high of $41.02. The company has a quick ratio of 1.
18, a current ratio of 1.18 and a debt-to-equity ratio of 0.74.
The company has a 50 day moving average of $15.82 and a 200 day moving average of $18.60.
Insider Buying and Selling at Fortrea In other news, CEO Thomas Pike sold 11,268 shares of the business’s stock in a transaction that occurred on Monday, January 13th. The shares were sold at an average price of $18.04, for a total transaction of $203,274.
72. Following the completion of the transaction, the chief executive officer now directly owns 159,868 shares of the company’s stock, valued at $2,884,018.72.
The trade was a 6.58 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website .
In the last 90 days, insiders have sold 12,386 shares of company stock worth $219,751. Company insiders own 0.12% of the company’s stock.
Wall Street Analysts Forecast Growth Several equities research analysts recently weighed in on FTRE shares. The Goldman Sachs Group reduced their price target on Fortrea from $22.00 to $11.
00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Citigroup downgraded shares of Fortrea from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $30.00 to $23.
00 in a research report on Wednesday, December 11th. William Blair reissued a “market perform” rating on shares of Fortrea in a research report on Tuesday, March 4th. Evercore ISI cut their price objective on shares of Fortrea from $20.
00 to $15.00 and set an “in-line” rating on the stock in a report on Tuesday, March 4th. Finally, Baird R W lowered shares of Fortrea from a “strong-buy” rating to a “hold” rating in a report on Friday, December 6th.
One research analyst has rated the stock with a sell rating and eleven have issued a hold rating to the company’s stock. Based on data from MarketBeat.com, Fortrea presently has a consensus rating of “Hold” and a consensus target price of $19.
00. View Our Latest Report on FTRE Fortrea Company Profile ( Free Report ) Fortrea Holdings Inc, a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services.
The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. Further Reading Want to see what other hedge funds are holding FTRE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Fortrea Holdings Inc.
( NASDAQ:FTRE – Free Report ). Receive News & Ratings for Fortrea Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortrea and related companies with MarketBeat.com's FREE daily email newsletter .
.
